Increased Expression of Serglycin in Specific Carcinomas and Aggressive Cancer Cell Lines

Figure 1

(a) Expression of serglycin across twelve cancer cell lines of lung (NCI-H23, NCI-H661, A549, and NCI-H358), breast (MCF-7, MDA-MB-231, and MDA-MB-468), prostate (PC-3), and colon (HT-29, CACO-2, and DLD-1). Results are mean of three separate experiments performed in triplicate ± S.D. (b) Equal amounts of protein from concentrated cell culture supernatants of cancer cell lines were treated with chondroitinase ABC and subjected to western blot analysis for serglycin using chondroitinase ABC digested standard serglycin (st1 and st2) as positive control. (c) Quantification of serglycin secreted in cell culture supernatants. Results are mean of three separate experiments performed in triplicate ± S.D. (d) Detection of serglycin gene transcripts by RT-PCR. The PCR products were analyzed on 1% agarose gels stained with GelRed.

(a)

(b)

(c)

(d)